Holen Sie sich die Stockscreener-App
2.31
2.67%
0.06
Handel nachbörslich:
2.31
Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate - Moomoo
Compass Therapeutics (CMPX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
HC Wainwright Issues Pessimistic Estimate for CMPX Earnings - MarketBeat
Compass Therapeutics Inc. (CMPX) Stock News Today - TradingKey
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
A Quick Look at Today's Ratings for Compass Therapeutics(CMPX.US), With a Forecast Between $6 to $7 - Moomoo
Compass Therapeutics (NASDAQ:CMPX) Price Target Raised to $6.00 at Piper Sandler - MarketBeat
Compass Therapeutics Inc. (CMPX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Compass Therapeutics (CMPX) Gains 4.5% to $2.08 as Buyers Defend Key Support LevelInstitutional Flow Picks - dars.gov.et
Compass Therapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 359% Upside - TradingView
Compass Therapeutics, Inc. Q2 2026 Financial Results: Balance Sheet, Losses & Key Highlights from CMPX 10-Q Filing - Minichart
Form 8K Compass Therapeutics, Inc. For: 6 August By Investing.com - Investing.com Nigeria
Compass Therapeutics, Inc. 2026: Revenue ($25.25M), Net income ($25.15M), EPS ($0.13) — 10-Q Summary - tradingview.com
Compass Therapeutics (NASDAQ: CMPX) details Q2 loss and BTC trial gains - stocktitan.net
CMPX: Strong pipeline progress and solid cash position support continued clinical development - TradingView
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update - Yahoo Finance
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewir - The National Law Review
Compass Therapeutics (CMPX) Projected to Announce Earnings on Monday - MarketBeat
Compass Therapeutics Inc. (CMPX) Institutional Confidence - TradingKey
CMPX Q2'26 Earnings: revenue estimate is (600.00K USD) - TradingView
CMPX|Compass Therapeutics Inc.|Price:1.885|Chg%:-0.025 - TradingKey
Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compass Therapeutics Inc. (CMPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CMPX|Compass Therapeutics Inc.|Price:2.080| - TradingKey
TradingKey - TradingKey
Compass Therapeutics Inc. (CMPX) Income Statement - TradingKey
Compass Therapeutics Inc. (CMPX) Balance Sheet - TradingKey
CMPX|Compass Therapeutics Inc.|Price:2.092|Chg%:+0.022 - TradingKey
Compass Therapeutics, Inc. Revenue Breakdown – NASDAQ:CMPX - TradingView
CMPX Q1 2026 Earnings: Narrow EPS Beat as Clinical-Stage Biotech Continues Pipeline DevelopmentStrong Earnings Momentum - po-news-eg.net
Compass Therapeutics Inc. (CMPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Monashee Investment Management LLC Sells 741,135 Shares of Compass Therapeutics, Inc. $CMPX - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Compass Therapeutics (CMPX) Slides 2.38% as Support Levels Come Into FocusFair Value Gap - dars.gov.et
Enterprise value to EBIT forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Compass Therapeutics (CMPX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Compass Therapeutics to present Phase 2/3 tovec... - Pluang
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 - The Manila Times
Compass Therapeutics’ COMPANION-002 Biliary Tract Cancer Study Accepted for Oral Presentation at ESMO 2026 - Quiver Quantitative
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity - Seeking Alpha
Compass Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesInvestor Earnings Call - DonanımHaber
Compass Therapeutics Inc. (CMPX) Q1 2026 Earnings: Narrower-Than-Expected Loss Reinforces Clinical-Stage Focus - dars.gov.et
Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Compass Therapeutics Inc. (CMPX) Q1 2026 Earnings: Narrower-Than-Expected Loss Driven by Disciplined SpendingHigh Estimate Range - dars.gov.et
Compass Therapeutics (CMPX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
If You Invested $1,000 in Compass Therapeutics Inc (CMPX) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX) - Insider Monkey
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):